First Korean patent approval for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the Korean Intellectual Property Office (KIPO), implying the company’s first patent approval in Korea. The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint” covers Episurf Medical’s 3D-based damage marking technology which constitutes a central part of the Episealer® implant system as well as the Epioscopy® joint visualisation system. “This is a core patent for Episurf’s imaging technology. We are working towards being able to launch our products